This trial is testing a new way to treat brain cancer that involves breaking down the barrier that protects the brain. They will do this in patients who are also receiving immunotherapy.
- Brain Tumor
2 Primary · 3 Secondary · Reporting Duration: up to 6 months
Awards & Highlights
2 Treatment Groups
Control Arm (Pembrolizumab only)
1 of 2
Pembrolizumab with Exablate BBBD
1 of 2
20 Total Participants · 2 Treatment Groups
Primary Treatment: Pembrolizumab with Exablate BBBD · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18 - 100 · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Could you give me a ballpark number of how many places this trial is happening?
"There are 4 recruiting patients for this trial including Sunnybrook Research Institute in Toronto, St. Joseph's Hospital and Medical Center in Phoenix, and University of Maryland in Baltimore, along with other locations." - Anonymous Online Contributor
Are octogenarians eligible for this clinical trial?
"Based on the age restrictions listed in the inclusion criteria, the minimum age to participate in this clinical trial is 18 and the maximum age is 100." - Anonymous Online Contributor
Has the FDA cleared Pembrolizumab in combination with Exablate BBBD for patient use?
"Pembrolizumab with Exablate BBBD is considered to be safe (scoring a 3 on our 1-to-3 scale) because it has progressed to Phase 3 clinical trials. This means that not only is there some evidence of its efficacy, but also that there have been multiple rounds of testing confirming its safety." - Anonymous Online Contributor
Who meets the selection criteria for this clinical trial?
"This clinical study is seeking 20 patients with brain neoplasms who are between the ages of 18 and 100. In addition to meeting this age criteria, participants must also meet the following requirements: The participant provides written informed consent for the trial, Participant is willing to comply with all study procedures for the duration of the study, Screening/Baseline laboratory values, Subject has tumor biomarkers that are EGFR (epidermal growth factor receptor) and ALK (anaplastic lymphoma kinase) negative, Participant is a NSCLC subject prescribed pembrolizumab monotherapy per standard of care, Participant is" - Anonymous Online Contributor